Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2017

View Archived Issues

Use of virus-specific T cells proves safe and effective for treating viral infections after HSCT

Use of 3D printing of aqueous droplets for low-cost tissue engineering

FDA approves Vabomere for complicated urinary tract infections

MilliporeSigma collaborates with Angiex to support development of ADC therapy for cancer

Yisheng reports promise of YS-ON-001 in multiple animal models of solid tumors

Treating angina with ivabradine/metoprolol FDC shows promise

FDA approves CAR-T cell therapy Kymriah for B-cell precursor ALL in children and young adults

FDA approval for Actemra to treat CAR T-cell-induced cytokine release syndrome

Merck & Co. glycoconjugate delivers insulin depending on glucose levels

AP-14145 shows selective SK channel targeting

CSL Behring to acquire Calimmune

Regenacy Pharmaceuticals discloses novel HDAC inhibitors

FDA accepts for review sNDA to add OS data to Kyprolis label

Kyowa Hakko Kirin presents antisense oligonucleotides as CFB supressors

Innovent Biologics divulges anti-PD-1 antibodies for treating cancer

FDA approves Austedo to treat tardive dyskinesia in adults

Institut National de la Recherche Agronomique discovers Enterococci to treat respiratory disorders

University of North Carolina at Chapel Hill discloses siRNAs targeting KRAS

Phase III trial of Otividex in Meniere's disease misses primary endpoint

University of California, Oakland divulges new vectors encoding LAMP-2 isoforms

Johns Hopkins University presents mutant GAPDH for treating liver cancer

Bioverativ studies BIVV-001 for severe hemophilia A in phase I/IIa trial

Phase II trial explores use of MBS-2320 in active rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...